PeptiDream Inc.
Research PeptiDream Inc. (4587.T) on Bullrun: market cap JPY 137.81B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4587.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 137.81B
- Financial periodFY2025
- RevenueJPY 18.52B
- Revenue growth-60.3%
- Net income-JPY 3.75B
- Free cash flow-JPY 15.03B
- Gross margin40.6%
Valuation Snapshot
latest market cap is JPY 137.81B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 18.52B | -JPY 3.75B | -JPY 15.03B | 40.6% | -28.99 | JPY 28.68B | JPY 17.04B | JPY 51.53B |
| FY2024 | JPY 46.68B | JPY 15.01B | JPY 21.63B | 73.9% | 115.68 | JPY 48.12B | JPY 19.63B | JPY 56.76B |
| FY2023 | JPY 28.71B | JPY 3.04B | JPY 11.05B | 60.0% | 23.38 | JPY 19.51B | JPY 22.22B | JPY 40.35B |
| FY2022 | JPY 26.85B | JPY 7.55B | -JPY 4.06B | 67.5% | 58.14 | JPY 5.25B | JPY 21.05B | JPY 32.04B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 137.81B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About PeptiDream Inc.
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PeptiDream Inc.'s market cap?
PeptiDream Inc.'s market capitalization is JPY 137.81B.
What does PeptiDream Inc. do?
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery campaigns.